Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Providing Tools to Stemina for Metabolomic Studies

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent Technologies said yesterday that it is providing tools to Stemina Biomarker Discovery to accelerate its metabolomic research.

Agilent will provide Stemina with a 1290 Infinity UHPLC platform for the separation of stem cell metabolites, and a 6530 Q-TOF mass spec for the identification of metabolites. In addition, Agilent is providing Mass Profile Profession software for interpreting complex data generated from metabolomic research.

Based in Madison, Wis., Stemina uses metabolomic analysis of stem cells to discover biomarkers for use in drug screening and drug development.

In a statement, Gustavo Salem, vice president and general manager for Agilent's Biological Systems Division, said that metabolomics is a "major growth area" for the company, "and the innovative work being done at Stemina is the kind we like to support."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.